U.S. Markets closed

8 Health-Care Stocks for Your Portfolio

Nellie S. Huang, Senior Associate Editor, Kiplinger's Personal Finance

Health care stocks cover a lot of bases. They're defensive because people always need medicine and medical care. They're fast-growing because innovative treatments are powering profits at several drug companies. And now, they're cheap, too.

See Also: Health Care Stocks: Now Is the Time to Buy

Scrutiny of the health care system is high, thanks in part to the upcoming 2020 presidential election, and that has weighed on the sector's stocks. From talk of Medicare for All to legal challenges to the Affordable Care Act to proposed drug-price regulations, "there's a lot of political noise," says Baron Health fund manager Neal Kaufman. As a result, shares in many good companies that were once expensive are now a bargain. "This is a great opportunity to buy stocks that are being punished unnecessarily," Kaufman says.

Few industry watchers believe Medicare will be nationalized. What will happen with the ACA or drug pricing is harder to predict. Even so, some pockets of the health care sector face greater uncertainty as the debate continues. Hospitals and businesses focused solely on insurance, for instance, would be at risk in a single-payer system.

But an aging population and the breakneck pace of drug innovation bode well for other parts of the sector over the long term. The Food and Drug Administration approved more new drugs in 2018 than in any year before. Just as the internet disrupted multiple industries, including tech and retail, "health care is on the verge of initiating significant change," says Gary Robinson, a co-manager of Baillie Gifford U.S. Equity Growth Fund, which is available in many U.S. retirement plans

To cash in on these long-term trends, we scoured the sector and found eight good opportunities. The stocks we like fall into three broad health care areas: drugmakers, health care service providers, and medical device and equipment manufacturers. Their share prices may continue to bounce around, especially as we near the 2020 elections. Smart investors will buy more when shares dip. "If you have flexibility and you can pick your spots, you can make money," says Matt Benkendorf, chief investment officer at money management firm Vontobel Quality Growth. (All returns and data are through June 14.)

Drugmakers

Half of all health care stocks in the U.S. are drugmakers. They include big pharmaceutical firms and older biotechnology companies that are steady growers and pay dividends, as well as smaller, faster-growing biotech firms with one or two products on the market and riskier outfits with no commercial products yet.

The lines are starting to blur as the traditional pharma firms, which combine chemicals to make drugs, and the biotech companies, which tap organic elements such as cells to create therapies, are coming together through mergers, acquisitions and partnerships to cash in on drug innovation. Gene sequencing and other advancements have changed the way we treat cancer, congenital diseases and other ailments, and "the level of innovation is accelerating," says Damien Conover, Morningstar's director of health care stock research.

Figuring out which companies will thrive, however, can be tricky. A good drug company has two key attributes: a stable of drugs with patent-expiration dates that are years away, and a fat pipeline of new drugs nearing FDA approval. But drugs and the diseases they treat are complicated. And success often breeds stiff competition. "Behind a lot of blockbusters are a lot of fast followers," says Jim Golan, comanager of William Blair Large Cap Growth fund.

It doesn't help that drug prices are under a microscope. Thanks in part to the current administration's efforts to lower the price Medicare customers pay for some drugs, "the pricing power of pharma firms has been stopped," says Edward Yoon, manager of Fidelity Select Health Care Portfolio. That's one reason Yoon, among others, eschews big pharma in his fund. Still, big drugmakers with a slew of products will weather changes in pricing and reimbursement better than companies with thin product lines. Smaller outfits that offer life-transforming drugs for rare diseases may also come through with less damage.

See Also: 10 Cancer-Fighting Health Care Stocks to Buy

Merck (symbol MRK, price $83) is an elder statesman in the pharma world that should continue to thrive in the new order. Keytruda, Merck's immunotherapy drug that basically gets the immune system to kill cancer cells, is "rapidly becoming one of the largest products we've ever seen," says JPMorgan Chase analyst Christopher Thomas Schott. The drug is currently approved to treat 11 types of tumors, including advanced non-small-cell lung cancer and melanoma.

In the drug world, a medicine is a blockbuster if it surpasses $1 billion in annual sales. Last year, Keytruda hit $7 billion. Morningstar expects it to reach $16 billion in 2022. And that number could rise. Scientists are testing Keytruda, alone and in combination with other therapies, for dozens of diseases in more than 1,000 studies. And Merck has time to cash in. The oldest patent on Keytruda doesn't expire until 2028.

Merck also makes vaccines that are big cash generators and are less subject to drug-pricing pressures. In 2018, sales of Gardasil, the cervical cancer vaccine, jumped 37% from the year before to hit $3.2 billion. The firm also has an animal health unit, which doesn't suffer from the regulatory uncertainty that vexes the human side of the business. The pet and livestock business represents only 10% of the company's overall operations, but it's growing faster than Merck's drug unit.

Merck shares trade at 16 times estimated 2020 earnings--a premium to shares of its large-company pharmaceutical peers, which trade at an average of 14 times 2020 earnings. But Merck is growing faster. Over the next three years, analysts expect earnings to increase 8.9% per year, on average, which is better than the 8.2% rate of other large pharma firms.

Biotech company Vertex Pharma­ceuticals (VRTX, $170) has a lock on treatments for cystic fibrosis, or CF, a rare lung disease caused by a gene mutation. The company's drugs are transformational. CF treatment was once limited to alleviating the symptoms of the disease. But Vertex's therapies treat the underlying cause of the disease by trying to allay the gene mutation. Of the estimated 75,000 CF cases worldwide, Vertex makes three drugs that treat 34,000 cases.

See Also: 11 Biotech Stocks to Put on Your Radar Soon

Its reach is expanding. The company has a new drug referred to as the "triple combination," which is expected to win approval in the U.S. in 2020 and could nearly double the number of CF cases Vertex treats, says CFRA analyst Kevin Huang. "With the likely approval of the triple, Vertex would cement its dominant position as the only real player in developing targeted therapy for CF," says Credit Suisse analyst Evan Seigerman.

In the meantime, the business is healthy. Vertex has $3.2 billion in cash and little debt. Analysts expect Vertex earnings to increase an average of 22.5% per year over the next three years, way ahead of the average 17.8% growth rate for its peer group, biomedical-genetics drug companies.

A smaller biotech firm with no profits--yet--fills out our drugmaker favorites. Neurocrine Biosciences (NBIX, $84) is expected to be profitable in 2020. It has two drugs on the market and a strong pipeline of therapies in all stages of development. One of its commercial drugs, Ingrezza, is a "best in class" therapy for tardive dyskinesia, a condition that causes jerky, involuntary face and body movements, says Credit Suisse's Seigerman. He thinks it could fetch annual sales of $2 billion by the early 2020s.

Neurocrine also has Orilissa, a drug for endometriosis pain, which Seigerman believes could be a market leader. Neurocrine won't rake in every dollar made on Orilissa sales, because the firm partnered with AbbVie to market the drug, but it will earn a meaningful royalty. Neurocrine is Seigerman's top pick in the small and midcap biotech category. He expects strong revenue growth of 31% annualized over each of the next five years.

Health care services

We're in the early days of a revolution that could one day lower overall health care costs for everyone. In today's health care system, a doctor and a hospital are most often paid to treat a patient who already suffers from an illness. In the future, prevention and continuing care--some call it holistic care--will take precedence.

The new health care model will only work if every p in the system--patients, providers (doctors, hospitals) and payers (insurers)--work together to make good decisions early, so healthy patients can stay well, and out of the hospital, longer. A healthier population, the theory goes, will lead to fewer dollars overall spent on health care.

It's happening already in a handful of U.S. cities, including Austin, Denver, and parts of Ohio and Florida, says Yoon. In those areas, hospital admission rates and emergency room visits per 1,000 people (industry measures of the quality of care) have dropped significantly due to the alignment of the p's. Costs have come down, too, he adds. But it could be a generation before we see change on a national level. "What works in Texas may not work in New York. My expectation is that it will happen eventually, but it will take longer than anyone wants," says Yoon.

UnitedHealth Group (UNH, $245) stands at the center of this long-term trend. UnitedHealth has a stake in every p. Being the biggest health insurer in the country makes it a payer. It's a provider through its OptumHealth division, which offers medical services at urgent-care clinics and walk-in surgical-care centers. And its 50 million insured members are patients. UnitedHealth is essentially a microcosm of the country's health system.

See Also: 5 Hot-Running Health Insurance Stocks to Buy

OptumInsight is UnitedHealth's secret weapon. The business unit collects and analyzes treatment data that can be used to improve health care outcomes, thus lowering medical bills. "You call your insurer," says Andrew Adams, lead manager of Mairs & Power Growth fund, "and they'll have your entire medical history. Based on records from doctors, drug prescriptions and hospital records, they'll know the best course of action to deliver care to you more efficiently." At least, that's the idea.

CVS Health (CVS, $54) aims to give UnitedHealth a run for its money. It's best known for its drugstores--70% of people in the U.S. live within three miles of a CVS pharmacy--but it operates more than 1,000 walk-in clinics, too. With its acquisition of Aetna in late 2018, CVS is now also an insurer.

Both stocks are bargains. UNH shares trade at 16 times estimated earnings, a level not seen since 2014 and a rare discount for these premium shares. "UnitedHealth has always been expensive," says Mairs & Power's Adams, who loaded up on more shares when the stock sold off in early 2019. Analysts expect 12.7% annualized earnings growth over the next three years.

CVS took on debt to acquire Aetna for $70 billion, and consequently it did not raise its dividend in 2018, ending a 14-year record of consecutive annual increases. The integration of Aetna and the debt paydown will take time, says CFRA's Huang. (The completed merger has been challenged in court, but Huang expects the deal to remain mostly intact.) He rates the stock a "strong buy," in part because at the current price, it's a bargain. It trades near its 52-week low, sporting a 3.7% yield, and has a price-earnings ratio of 8--more than 40% below the stock's median historical P/E of the past 10 years. Meanwhile, earnings are expected to increase by an annualized 7.2% over each of the next three years.

Medical devices

Drugmakers are spending gobs of money to research and develop innovative therapies. Life sciences tool companies--a subset of the medical-devices industry--make "the picks and shovels" that enable that effort, says Jason Kritzer, comanager of Eaton Vance Worldwide Health Sciences fund. Analysts expect companies in this group to increase earnings over the next three years at a rate of 12% to 14% per year, on average, compared with 10% for companies in Standard & Poor's 500-stock index.

Size helps in the medical device world. A lack of funding has, in part, made it difficult for small device companies to survive on their own, and most are acquired by large companies. Accordingly, our favorites have heft in their favor.

See Also: Best Health Care Stocks to Buy for 2019

Thermo Fisher Scientific (TMO, $285) is a big kahuna in the life sciences industry. Record spending on biotech-drug research is fueling demand for the company's lab products and services, gene-sequencing instruments, analytical tools, and diagnostic kits. More than 80% of its revenue is tied to recurring sales of its consumable products (syringes, diagnostic tests and other single-use items) and services, says Chris Smith, manager of Artisan Thematic fund. That makes the company less vulnerable to economic swings, says Smith. Meanwhile, Thermo leads the sector in sales and earnings growth that is internally driven (and not attributable to acquisitions, say). Moreover, he adds, "we think TMO has the best management in the industry."

Analysts expect 12.5% profit growth annualized over the next three years. The stock trades at 23 times estimated earnings, compared with an average multiple of 36 for its peers in the medical instruments market.

After spinning off its drug division in 2013, Abbott Laboratories (ABT, $82) now focuses on a diverse roster of products that includes nutritional drinks, diagnostics, generic drugs and medical devices. But a trio of new products put it in the sweet spot of the health care sector's innovation surge, says William Blair's Golan.

One is FreeStyle Libre, a 14-day wearable continuous glucose monitor that does away with finger pricks and tracks patterns and trends over time, helping patients manage their diabetes better. Another is MitraClip, a device that allows patients with a certain heart condition to get treatment with less-invasive surgery (in other words, not open-heart surgery). It has no competition, says William Blair analyst Margaret Kaczor, and a recent FDA decision doubles the number of eligible patients for the device. The third of the trio, Alinity, is a next-generation diagnostic system that integrates and streamlines the workflow of a diagnostic lab, using analytics and automation to standardize research processes, reduce costs and manage labor constraints.

Abbott proves that even giant companies can be innovative. More than 50% of the firm's sales come from products that launched within the past six years. Analysts expect annualized profit growth of 12.3% over each of the next three years.

Intuitive Surgical (ISRG, $497) is a leader in minimally invasive, robot-assisted surgery. Surgeons perform operations--urological and gynecological procedures, among others--using the company's technically advanced instruments and 3D, high-definition vision capability known as the da Vinci system. "This market is in its infancy," says Samantha Pandolfi, a comanager of Eaton Vance Worldwide Health Sciences. Of the 60 million general surgical procedures performed worldwide last year, almost a million were conducted with the da Vinci system. "There's a long runway for growth, and the company's lead over the competition is wide," she says. "We think it can sustain double-digit sales and earnings growth for a very long time." Analysts, according to Zacks Research, expect 12.2% earnings growth, on average, over each of the next three years.

Invest with a specialist

The outcomes for small, go-go biotech firms can be extreme--you either win big or you lose everything--and the work they do is complex. You might appreciate a fund with an expert at the helm who has the experience and resources to understand and weigh the risks.

Ed Yoon has been analyzing health care companies for over a decade, and has run Fidelity Select Health Care Portfolio (FSPHX) since 2008. The fund has delivered above-average returns with below-average volatility under Yoon; its 10-year, 18.3% annualized return beats 90% of all health care funds. Yoon takes big stakes in steady, large companies that provide ballast for the smaller bets he makes on burgeoning biotech firms. Biotech firms, health care services companies (including insurers), and medical instruments and device makers represent the biggest chunks of the fund.

As manager of Janus Henderson Global Life Sciences (JAGLX), Andy Acker has been researching health care companies for more than two decades (he comes from a family of physicians, too). He spreads his investments across the sector, keeping one-third of the portfolio in drugmakers, one-third in biotech firms, and the rest in health care services and medical devices. Over the past 10 years, Janus's annualized return beat 78% of its peers.

EDITOR'S PICKS

Copyright 2019 The Kiplinger Washington Editors

  • Oil Price Fundamental Daily Forecast –	Slight Rise Indicates Traders Downplaying Recession Concerns
    Business
    FX Empire

    Oil Price Fundamental Daily Forecast – Slight Rise Indicates Traders Downplaying Recession Concerns

    U.S. West Texas Intermediate and international-benchmark Brent crude oil futures are trading better on Friday after gapping yesterday's close. At 08:09 GMT, October WTI crude oil is trading $55.15, up $0.73 or +1.38% and December Brent crude oil is at $57.90, up $0.56 or +0.98%. On Thursday, the U.S. reported that retail sales rose 0.7% in July as consumers bought a range of goods even as they cut back on motor vehicle purchases, according to data that came a day after the 2-year/20-year U.S. Treasury yield inverted for the first time since June 2007 prompting a sell-off in stocks and crude oil.

  • Textron Aviation ready to assist in investigation of Dale Earnhardt Jr.’s plane crash
    Finance
    American City Business Journals

    Textron Aviation ready to assist in investigation of Dale Earnhardt Jr.’s plane crash

    Wichita-based Textron Aviation says it is ready to help in the investigation of crash Thursday of a Cessna Citation Latitude business jet carrying famed NASCAR racer Dale Earnhardt Jr. and his family. “Textron Aviation works closely with government aviation authorities responsible for accident investigations and has offered assistance to the National Transportation Safety Board in response to yesterday's accident in Tennessee,” a company spokesperson tells the WBJ. “As a party to the investigation, the company is prohibited by regulation from divulging any information about the accident or investigation.” Earnhardt, his wife and daughter, and two pilots were able to escape the plane after it crashed off the end of the runway after landing Thursday afternoon at Elizabethton Municipal Airport in Elizabethton, Tenn.  The locally built Latitude subsequently caught on fire.  According to a report from the Tennessean, Earnhardt was taken to a hospital for observation but soon released and no injuries were reported to any of the plane's other occupants.  "The first word to come to my mind is that they were very lucky," Elizabethton Fire Chief Barry Carrier told the publication.

  • Trump isn’t the first US president to want to buy Greenland
    World
    Quartz

    Trump isn’t the first US president to want to buy Greenland

    The plan doesn't sound plausible, most notably because Greenland is not for sale, as the territory's Ministry of Foreign Affairs explained in a tweet today (Aug. 16). #Greenland is rich in valuable resources such as minerals, the purest water and ice, fish stocks, seafood, renewable energy and is a new frontier for adventure tourism. “If [Trump] is truly contemplating this, then this is final proof, that he has gone mad,” foreign affairs spokesman for the Danish People's Party, Soren Espersen, told the national broadcaster.

  • United Airlines prepping for big Chicago Bears celebration
    News
    American City Business Journals

    United Airlines prepping for big Chicago Bears celebration

    United Airlines' base of operations in Terminal 1 at Chicago's O'Hare International Airport is getting a new temporary resident as of Monday. A seven-foot-tall bobblehead of the late Bill George, a former Chicago Bears linebacker and star player during the 1950's, will be set up in Concourse B near TSA security checkpoint 3 and will remain there through Aug. 27. The bobblehead of George is making an appearance at O'Hare as part of the Bears' 100th anniversary celebration.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of BLIN earnings conference call or presentation 14-Aug-19 8:30pm GMT

    Roger E. Kahn, Bridgeline Digital, Inc. - President, CEO & Director [3] Thank you, Mark, and good afternoon, everyone.

  • 3 High-Growth Stocks That Are Just Getting Started
    Business
    Motley Fool

    3 High-Growth Stocks That Are Just Getting Started

    Powering the rise of solar energy Maxx Chatsko (Enphase Energy): Sure, shares of Enphase Energy have soared 580% since the beginning of the year, but first-half 2019 operating results suggest there's plenty of room to run. The solar hardware provider reported 60% year-over-year revenue growth and a nearly $28 million increase in operating income in that span. The most recent quarterly results actually exceeded management's long-term targets for gross profits, operating expenses, and operating income, but CEO Badri Kothandaraman said he's going to wait a few more quarters before setting new operating targets.

  • What Kind Of Investor Owns Most Of Surge Energy Inc. (TSE:SGY)?
    Business
    Simply Wall St.

    What Kind Of Investor Owns Most Of Surge Energy Inc. (TSE:SGY)?

    What Does The Institutional Ownership Tell Us About Surge Energy? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

  • Does Herbalife Nutrition Ltd.'s (NYSE:HLF) P/E Ratio Signal A Buying Opportunity?
    Business
    Simply Wall St.

    Does Herbalife Nutrition Ltd.'s (NYSE:HLF) P/E Ratio Signal A Buying Opportunity?

    Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. Herbalife Nutrition has a price to earnings ratio of 16.84, based on the last twelve months. How Do I Calculate A Price To Earnings Ratio?

  • Business
    Benzinga

    Box-Ship Giant Maersk Reports Huge Rise In Second Quarter Profit

    Earlier today in Europe, Danish shipping giant A.P. Moller–Maersk reported a massive increase in second quarter underlying profit and earnings before interest, tax, depreciation and amortization. Maersk today reported slight growth in second quarter revenues to US$9.6 billion "which is on par with last year," the group said.

  • General Electric shares bounce back after Markopolous report
    Business
    Yahoo Finance Video

    General Electric shares bounce back after Markopolous report

    Shares of General Electric are bouncing back just one day after whistleblower Harry Markopolous published a report accusing the company of massive accounting fraud. Wall Street analysts are coming to General Electric's defense. Yahoo Finance's The Ticker discusses.

  • China Ramps Up Brazil Soybean Imports, Rebuffing U.S. Crops
    Business
    Bloomberg

    China Ramps Up Brazil Soybean Imports, Rebuffing U.S. Crops

    China is stepping up its soybean buying in Brazil as growers in Argentina continue to hoard and the Asian nation avoids American oilseed after an escalation in trade tensions between Washington and Beijing. Private and state-owned companies bought 25 to 30 cargoes of soy from Brazil this week through Thursday, according to people familiar with the matter, who asked not to be identified because the deals are private. Brazilian orders come after China, the top importer, stopped purchasing American soy as the spat with the U.S. deepens and farmers in Argentina are withholding beans as a hedge against currency depreciation due to election uncertainty.

  • Business
    Motley Fool

    3 Top Healthcare Stocks to Buy in August

    The healthcare industry has a reputation for being fairly resistant to recessions. Both economic fears and company-specific issues can send a company's stock price tumbling. With that in mind, we asked three Motley Fool contributors to each pick a healthcare stock that looks worthy of purchasing this August.

  • Here’s what smart rich people really do with their nest egg
    Business
    MarketWatch

    Here’s what smart rich people really do with their nest egg

    Most people think they're above average in intelligence, relationship status and professional achievement. Social scientists call this “illusory superiority.” My business partner Scott Puritz, has found the one area where even above-average people, objectively smart, rich, successful professionals, seem to wave the white flag and admit to not understanding — money and investing. “One of the most shocking things is the low-level financial literacy throughout our culture,” Puritz told the Washington Post.

  • Rental firm walks away from Tesla order after quality dispute
    Business
    Reuters

    Rental firm walks away from Tesla order after quality dispute

    Car rental company Nextmove has walked away from a 5 million euros ($5.55 million) order for 85 Tesla Model 3 electric vehicles following a dispute over how to fix quality issues, the German company said on Friday. Nextmove said it had ordered 100 electric vehicles in 2018 but raised objections over quality and finish after taking delivery of the first 15 Model 3 cars earlier this year. The rental company said following a dispute over how to resolve the quality shortcomings, Tesla triggered a refund clause but Tesla disputes that it cancelled the order.

  • Analysts’ Views on General Motors and Ford
    Business
    Market Realist

    Analysts’ Views on General Motors and Ford

    General Motors (GM) and Ford (F) stocks have been impacted by the companies' dull second-quarter earnings. Of the 20 and 19 analysts covering GM and Ford, 70% and 42% recommend “buy” or “strong buy.” Of the analysts covering Ferrari (RACE) and Fiat Chrysler (FCAU), 67% recommend “buy” or “strong buy.” Meanwhile, Tesla (TSLA) has been rated as “buy” or “strong buy” by 31% of analysts covering the stock. Price targets for auto stocks Analysts' price target for GM implies higher gains than does their Ford price target.

  • Kratos Defense Stock Upgraded: What You Need to Know
    Business
    Motley Fool

    Kratos Defense Stock Upgraded: What You Need to Know

    Fast-growing small-cap stock Kratos Defense and Security Solutions (NASDAQ: KTOS), for example, is up 42% over the past year, but down 23% for the month of August! And yet, according to one analyst, this sell-off in Kratos shares provides investors an opportunity to buy a high-quality growth stock at an attractive price. Indeed, as Goldman argues in a note covered on TheFly.com, as early as 2020 we could see "substantial" growth in Kratos' unmanned aerial vehicles business -- and the company could continue growing sales at rates of anywhere from 23% to 30% annually through 2023. Result: Not only does Goldman Sachs think we will soon see Kratos return to its recent high of $24.65 per share, the analyst even believes Kratos could fly higher -- hitting perhaps $26 within a year, and delivering as much as a 36% profit to investors who buy today.

  • Nvidia surges on earnings beat despite gaming revenue decline
    Business
    Yahoo Finance Video

    Nvidia surges on earnings beat despite gaming revenue decline

    Nvidia posted better-than-expected fiscal-second quarter earnings. Yahoo Finance's Dan Howley joins Akiko Fujita on 'The Ticker' to discuss.

  • Why Novavax Stock Is Soaring Today
    Business
    Motley Fool

    Why Novavax Stock Is Soaring Today

    Shares of the clinical-stage biotech Novavax (NASDAQ: NVAX) are up by 10.65% as of 10:34 a.m. EDT today. Novavax's shares have been bolting higher of late in response to a newly released clinical update for the company's experimental respiratory syncytial virus (RSV) vaccine known as ResVax. Based on how Novavax's stock has reacted to this clinical update, investors seem to be under the impression that the company may now be able to find a viable regulatory pathway for ResVax in either the U.S. or another high-value market abroad.

  • Aurora Cannabis’s Target Price and Valuation
    Business
    Market Realist

    Aurora Cannabis’s Target Price and Valuation

    As of yesterday, Aurora Cannabis (ACB) stock was trading at 7.63 Canadian dollars. Despite the company providing higher-than-expected guidance for fiscal 2019's fourth quarter this year, its stock has fallen 25.6% this month. Why Aurora's stock price fell

  • ‘From bad to worse’: Analysts slash Canopy Growth price targets
    Business
    Yahoo Finance Canada

    ‘From bad to worse’: Analysts slash Canopy Growth price targets

    Analysts are slashing their price targets on shares of Canopy Growth Corp. (WEED.TO)(CGC) after quarterly results fell short of expectations on multiple fronts. The Smiths Falls, Ont.-based cannabis producer's fiscal first quarter was marked by declining revenue, shrinking gross margins, waning market share and a hefty $1.28 billion one-time accounting charge. “Among the seven licensed producers that have thus far reported calendar 2Q19 earnings, WEED is one of only two (the other being Organigram) to post a sequential revenue decline,” Cowen analyst Vivien Azer wrote in a research note.

  • Here's Why Schlumberger (NYSE:SLB) Has A Meaningful Debt Burden
    Business
    Simply Wall St.

    Here's Why Schlumberger (NYSE:SLB) Has A Meaningful Debt Burden

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. Importantly, Schlumberger Limited (NYSE:SLB) does carry debt. Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price.

  • Why New Residential Investment Corp. (NYSE:NRZ) Could Be Your Next Investment
    Business
    Simply Wall St.

    Why New Residential Investment Corp. (NYSE:NRZ) Could Be Your Next Investment

    In the case of NRZ, it is a company with a buoyant growth outlook, which has not yet been reflected in the share price. For those interested in digging a bit deeper into my commentary, read the full report on New Residential Investment here. NRZ's shares are now trading at a price below its true value based on its discounted cash flows, indicating a relatively pessimistic market sentiment.

  • Copper Mountain Mining Corporation (TSE:CMMC) Insiders Increased Their Holdings
    Business
    Simply Wall St.

    Copper Mountain Mining Corporation (TSE:CMMC) Insiders Increased Their Holdings

    So we'll take a look at whether insiders have been buying or selling shares in Copper Mountain Mining Corporation (TSE:CMMC). What Is Insider Selling? Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company.

  • Chevrolet unveils price of 2020 midengine Corvette
    Business
    USA TODAY

    Chevrolet unveils price of 2020 midengine Corvette

    Chevrolet is taking preorders for the much-anticipated midengine Corvette and has dedicated a "concierge" team to answer customer inquiries about the sports car. General Motors said Thursday its 2020 Chevrolet Corvette Stingray will start at $59,995. “Most people thought when we moved the Corvette to midengine it would no longer be attainable, but we knew we couldn't mess with a winning formula, and the 2020 Stingray proves it,” said Brian Sweeney, Chevrolet U.S. vice president.

  • How Safe Is ExxonMobil's Dividend?
    Business
    Motley Fool

    How Safe Is ExxonMobil's Dividend?

    Shares of energy goliath ExxonMobil (NYSE: XOM) are down around 15% from their highs earlier this year. Income investors may be wondering if there's something going on that they need to know about. The answer is yes and no. Here's what changed, and why Exxon and its dividend are still safe.